Genome Diagnostics B.V. Sustainability Profile
Genome Diagnostics B.V., commonly referred to as Gendx, is a leading player in the field of molecular diagnostics, headquartered in the Netherlands. Founded in 2012, the company has rapidly established itself as a key innovator in genetic testing, particularly in oncology and infectious diseases, serving both European and global markets. Gendx is renowned for its advanced diagnostic solutions, including next-generation sequencing (NGS) and PCR-based assays, which are designed to provide accurate and timely results. Their unique approach combines cutting-edge technology with a commitment to quality, ensuring that healthcare providers can make informed decisions based on reliable data. With a strong market position, Gendx has achieved significant milestones, including partnerships with prominent healthcare institutions and contributions to personalised medicine. Their dedication to innovation and excellence continues to drive their success in the ever-evolving landscape of genomic diagnostics.
DitchCarbon Score
How does Genome Diagnostics B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genome Diagnostics B.V.'s score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genome Diagnostics B.V.'s reported carbon emissions
Genome Diagnostics B.V., headquartered in the Netherlands, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Eurobio Scientific Société anonyme, which may influence its climate-related strategies and commitments. As of now, Genome Diagnostics B.V. has not established any documented reduction targets or climate pledges. This lack of specific initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the context of the industry, it is essential for organisations like Genome Diagnostics B.V. to align with broader climate commitments and frameworks, such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), to enhance their sustainability profile and contribute to global emissions reduction efforts. In summary, while Genome Diagnostics B.V. does not currently report emissions data or specific climate commitments, its affiliation with Eurobio Scientific may provide a pathway for future climate initiatives and performance improvements.
How Carbon Intensive is Genome Diagnostics B.V.'s Industry?
How Carbon Intensive is Genome Diagnostics B.V.'s Location?
Genome Diagnostics B.V.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Genome Diagnostics B.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
